NCT07069933Not yet recruitingPhase 2
Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?
"Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?"
Source: ClinicalTrials.gov · Last updated 17 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A prospective, randomized, controlled, parallel clinical trial will be conducted at Clinical Oncology and Nuclear Medicine Center at Mansoura University Hospital to assess the efficacy of Itraconazole as an adjuvant therapy in treatment of patients with acute myeloid Leukemia.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 14 Feb 2025
- Start date
- Jul 2025
- Primary completion date
- Jul 2025
- Lead sponsor
- Mansoura University
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07069933
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From Jul 2025 to the primary completion date, Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with any other types of malignancies rather than Leukemia and patients.
- Patients with documented hypersensitivity or allergy to Itraconazole.
- Patients suffer from chronic heart failure
Other
- Patients with history alcohol intake, acute or chronic.
- Patients present with severe dehydration.
- Patients with severe kidney dysfunction
Who the study is looking for
- Patients with Acute Myeloid leukemia, and aged 18 years or older
- Patients whose ECOG performance status ranged from 0-2 and are fit for all treatments protocols
Age in the registry: 18 years to 100 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Oncology and Nuclear Medicine of Mansoura University Hospital, Mansoura, Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.